注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Marinus Pharmaceuticals Inc是一家处于商业阶段的制药公司,专注于癫痫症治疗药物的开发。该公司的商业产品ZTALMY(加奈索龙)口服混悬液CV用于治疗两岁及以上患者与细胞周期蛋白依赖性激酶样5(CDKL5)缺乏症相关的癫痫发作。加奈索酮的潜力也正在其他罕见的癫痫发作中进行研究,包括在结节性硬化症和难治性癫痫持续状态的III期试验中。该公司的加奈索酮是一种神经活性类固醇γ-氨基丁酸A型(GABAA)受体调节剂,作用于已知具有抗癫痫作用的大脑中一个特征明确的靶点。该公司的加奈索酮也在静脉注射和口服制剂中进行开发,以最大限度地提高急性和慢性护理环境中成人和儿科患者的治疗范围。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Scott N. Braunstein | 59 | 2018 | CEO, President & Chairman |
Sarah B. Noonberg | 55 | 2023 | Independent Director |
Seth H. Z. Fischer | 68 | 2016 | Independent Director |
Charles E. Austin | 67 | 2020 | Independent Director |
Timothy M. Mayleben | 63 | 2008 | Lead Independent Director |
Saraswathy V. Nochur | 62 | 2021 | Independent Director |
Michael A. Rogawski | - | - | Member of Scientific Advisory Board |
Elia M. Pestana Knight | - | - | Member of Scientific Advisory Board |
Lawrence Hirsch | - | - | Member of Scientific Advisory Board |
Elizabeth Thiele | - | - | Member of Scientific Advisory Board |
Aatif M. Husain | - | - | Member of Scientific Advisory Board |
Eugen Trinka | - | - | Member of Scientific Advisory Board |
Christine B. Silverstein | 40 | 2023 | Independent Director |
Jacqueline A. French | - | - | Member of Scientific Advisory Board |
Marvin H. Johnson | 60 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核